Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Asterias Biotherapeutics

- PMLiVE

Pfizer’s Lorviqua recommended by NICE for lung cancer

Lung cancer is the leading cause of cancer-related deaths worldwide

- PMLiVE

Boehringer’s Hernexeos granted FDA accelerated approval for lung cancer patients

Approximately 226,650 lung cancer cases are expected to be diagnosed in the US this year

- PMLiVE

CHMP recommends BeOne Medicines’ Tevimbra for new lung cancer indication

Non-small cell lung cancer accounts for up to 90% of all lung cancer cases

- PMLiVE

AstraZeneca shares late-stage results for Tagrisso combination in lung cancer

An estimated 2.4 million people globally are diagnosed with lung cancer each year

- PMLiVE

FDA approves Dizal’s oral therapy Zegfrovy to treat advanced lung cancer

Around 226,650 new cases of lung cancer are expected to be diagnosed in the US this year

- PMLiVE

MHRA approves Accord Healthcare’s Hetronifly to treat aggressive form of lung cancer

Small cell lung cancer accounts for up to 15% of all lung cancer diagnoses

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Datroway granted FDA accelerated approval for lung cancer

Approximately 226,650 new cases of lung cancer will be diagnosed in the US this year

- PMLiVE

FDA approves Nuvation Bio’s TKI inhibitor Ibtrozi to treat rare form of lung cancer

ROS1-positive non-small cell lung cancer accounts for approximately 2% of new NSCLC cases

- PMLiVE

MHRA approves SFL’s Aumseqa to treat EGFR-mutated lung cancer in adults

Approximately 43,000 people are diagnosed with lung cancer every year in the UK

- PMLiVE

Roche/Jazz share positive phase 3 results for lung cancer combination therapy

Approximately 30,000 new cases of small cell lung cancer are reported in the US every year

- PMLiVE

Bristol Myers Squibb’s perioperative Opdivo regimen granted EC approval in NSCLC

Up to 55% of patients with non-metastatic NSCLC develop recurrence despite curative resection

- PMLiVE

Pfizer gains rights to 3SBio’s investigational bispecific antibody in deal worth over $6bn

The candidate is in clinical development for colorectal cancer, lung cancer and gynaecological tumours

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links